Overview

Trial of Oncaspar® and Three Doses of Pegylated Recombinant Asparaginase in Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukaemia

Status:
Terminated

Trial end date:
2013-05-01

Target enrollment:

Participant gender:

Summary

This is an assessment of efficacy and safety of three different doses of pegylated recombinant asparaginase (PEG-rASNase) in comparison to Oncaspar® during treatment of adults with de novo acute lymphoblastic leukaemia (ALL). This study will provide first data for determining specific asparaginase doses to yield various durations of L-asparagine (ASN) depletion which are required within different treatment phases of ALL therapy.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

medac GmbH

Treatments:

Asparaginase
Pegaspargase